A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
Richardson, Paul G.
Attal, Michel
Rajkumar, S. Vincent
San Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey S. Y.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Corzo, Kathryn Penkus
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth Carl
机构：
[1] Harvard Med Sch, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] IUCT Oncopole, Toulouse, France
[3] Mayo Clin, Rochester, MN USA
[4] Clin Univ Navarra, Navarra, Spain
[5] Ankara Univ, Ankara, Turkey
[6] Vseobecna Fak Nemocnice V Praze, Prague, Czech Republic
[7] CHRU Lille, Lille, France
[8] Oslo Univ Hosp, Oslo, Norway
[9] CHU Nantes, Hotel Dieu, Nantes, France
[10] Univ Athens, Athens, Greece
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Univ Hosp Olomouc, Olomouc, Czech Republic
[13] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
[14] Epworth Healthcare, Melbourne, Vic, Australia
[15] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[16] Sanofi R&D, Oncol, Vitry Sur Seine, France
[17] Sanofi, Cambridge, MA USA
[18] Sanofi US, Cambridge, MA USA
[19] Sanofi R&D, Vitry Sur Seine, France
[20] Sanofi, Vitry Sur Seine, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8004
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)
    Niederwieser, Dietger
    Richardson, Paul
    Attal, Michel
    Rajkumar, Vincent
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulosu, Meletios
    Huan, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Mace, Sandrine
    Prince, H. Miles
    Corzo, Kathryn P.
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 40 - 41
  • [2] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
    Attal, Michel
    Richardson, Paul G.
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Corzo, Kathryn P.
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth C.
    LANCET, 2019, 394 (10214): : 2096 - 2107
  • [3] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey S. Y.
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth C.
    BLOOD, 2022, 140
  • [4] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
    Richardson, Paul
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
  • [5] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
  • [6] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    van de Velde, Helgi
    Anderson, Kenneth C.
    LANCET ONCOLOGY, 2022, 23 (03): : 416 - 427
  • [7] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
    San-Miguel, Jesus F.
    Weisel, Katja C.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (vol 394, pg 2096, 2019)
    Attal, M.
    Richardson, P. G.
    Rajkumar, S., V
    LANCET, 2019, 394 (10214): : 2072 - 2072
  • [9] Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
    Richardson, Paul G.
    Siegel, David S.
    Vij, Ravi
    Hofmeister, Craig C.
    Baz, Rachid
    Jagannath, Sundar
    Chen, Christine
    Lonial, Sagar
    Jakubowiak, Andrzej
    Bahlis, Nizar
    Song, Kevin
    Belch, Andrew
    Raje, Noopur
    Shustik, Chaim
    Lentzsch, Suzanne
    Lacy, Martha
    Mikhael, Joseph
    Matous, Jeffrey
    Vesole, David
    Chen, Min
    Zaki, Mohamed H.
    Jacques, Christian
    Yu, Zhinuan
    Anderson, Kenneth C.
    BLOOD, 2014, 123 (12) : 1826 - 1832
  • [10] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).
    Shah, Jatin J.
    Jagannath, Sundar
    Mateos, Maria-Victoria
    Palumbo, Antonio
    Kher, Uma
    Marinello, Patricia Maria
    San Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345